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1098Background: The effect of prosthesis–patient mismatch (PPM) on clinical outcomes after aortic valve replace-
ment remains controversial. We evaluated effect of PPM on long-term clinical outcomes after isolated aortic
valve replacement in patients with predominant aortic stenosis.
Methods:We analyzed data from patients with predominant aortic stenosis who underwent isolated aortic valve
replacement between January 1995 and July 2010. The indexed effective orifice area, obtained by dividing the
in vivo effective orifice area by the patient’s body surface area, was used to define PPM as clinically nonsignif-
icant (group I, 224 patients), mild (group II, 52 patients), moderate (group III, 39 patients), and severe (group IV,
36 patients).
Results: Early survival was not significantly different among the groups, but overall survival was decreased
gradually in group IV. Overall survival at 12 years was lower in group IV than in group I (92.8%  2.7% vs
67.0  10.1, respectively; P ¼ .001). Cardiac-related-death-free survival at 12 years was lower in patients
with severe PPM. Left ventricular mass index decreased during the follow-up period in all groups. But left ven-
tricular mass index was less decreased in group IV compared with groups I, II, and III. Age, severe PPM, and
ejection fraction<40%, and New York Heart Association Functional Class IV were independent risk factors of
overall survival on multivariate analysis. Severe PPM was an independent risk factor for cardiac-related death.
Conclusions: Severe PPM showed an adverse effect on long-term survival, and was an independent risk factor
for cardiac-related death. In addition, patients with severe PPM showed less decreasing left ventricular mass
index during follow-up. (J Thorac Cardiovasc Surg 2013;146:1098-104)Prosthesis-patient mismatch (PPM) occasionally occurs
after aortic valve replacement (AVR). PPM is present
when the effective orifice area (EOA) of an implanted pros-
thetic valve is too small relative to body size, which conse-
quently generates higher pressure gradients through
a normally functioning prosthetic valve. This hemodynamic
change increases left ventricle work, reduces left ventricular
mass regression, and produces clinical symptoms of aortic
stenosis (AS). Several studies reported that PPM is an inde-
pendent risk factor for midterm mortality, or long-term sur-
vival after AVR.1,2 If the PPM combined with low left
ventricle function, short-term mortality was increased.3
But others demonstrated that severe PPM was predicted in
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Discrepancies may be related to differences in criteria used
to define PPM and to quantify its severity, or differences in
patient baseline characteristics. Our study was designed to
evaluate the effect of PPM on regression of left ventricular
mass index (LVMI) and long-term survival after AVR. To
minimize bias, particularly on long-term survival, we in-
cluded only patients who underwent isolated AVR for pre-
dominant AS in each group of our study since 1995 when
we began to use various types of prostheses. This study
was approved by the Institutional Review Board of Sever-
ance Hospital, Yonsei University Health System.
METHODS
Patient Selection
We analyzed data from 351 patients with predominant AS who under-
went isolated AVR between January 1995 and June 2010. Patients with
more than mild aortic regurgitation on preoperative transthoracic echocar-
diography were excluded, as were patients with significant coronary artery
disease who had undergone percutaneous coronary intervention or con-
comitant coronary artery bypass grafting surgery. Patients who underwent
other valvular surgery or ascending aorta graft replacement for poststenotic
dilatation also were excluded.
Prostheses
We used various prostheses beginning in 1995. The type and size of
prosthesis was recorded for each patient. The prostheses used weregery c November 2013
Abbreviations and Acronyms
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
EOA ¼ effective orifice area
LVMI ¼ left ventricular mass index
LVOT ¼ left ventricular outflow tract
PPM ¼ prosthesis–patient mismatch
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DCarpentier-Edwards S.A.V. (Edwards Lifescience, Irvine, Calif) in 89
patients (26%), St Jude Medical standard (St Jude Medical, Inc, St Paul,
Minn) in 80 patients (24%), ATS (ATS Medical, Inc, Minneapolis,
Minn) in 39 patients (11%), Carbomedics (Sulzer CarboMedics, Inc, Aus-
tin, Tex) in 35 patients (10%), St Jude Medical Epic (St Jude Medical, Inc)
in 22 patients (6.2%), EdwardsMIRA (Edwards Lifescience) in 17 patients
(4.8%), MCRI On-X (Medical Carbon Research Institute, Austin, Tex) in
18 patients (5%), Sorin Bicarbon (Sorin Biomedica Cardio Spa, Saluggia,
Italy) in 14 patients (4%), andMedtronic Hancock II (Medtronic, Inc, Min-
neapolis, Minn) in 9 patients (3%).
Doppler Echocardiographic Measurements
All patients underwent preoperative and postoperative 2-dimensional
and Doppler echocardiographic evaluation, and underwent serial follow-
up echocardiographic examination every 2 or 3 years, and as clinically
indicated after operation. The in vivo EOA for prosthesis type and size
was reported in previous studies of patients with normally functioning
prostheses.3,6-15 In our study, echocardiography was performed within
2 months after operation in all patients, the in vivo EOA was derived
from the continuity equation: (0.785 3 LVOT2 3 TVI1)/TVI2, where
LVOT is the diameter of the left ventricular outflow tract, and TVI1 and
TVI2 are the time–velocity integrals at the LVOT and across the aortic
valve, respectively. The left ventricular mass was derived from the
formula described by the American Society of Echocardiography:
0:83

1:04
ðLVIDþPWTþ IVSTÞ3LVID3þ0:6
in which LVID is left ventricular internal diameter, PWT is posterior wall
thickness, and IVST is interventricular septal thickness (all diastolic
measurements). Echocardiography was performed within 2 months after
operation.
PPM Definition
Indexed EOAwas obtained by dividing in vivo EOA by a patient’s body
surface area at the time of operation and was available for all patients. The
reference group comprised patients with an indexed EOA>0.85 cm2/m2
(group I, 224 patients). PPM was defined as mild if the indexed EOA
was 0.85 cm2/m2 but>0.75 cm2/m2 (group II, 52 patients), moderate if
indexed EOAwas0.75 cm2/m2 but>0.65 cm2/m2 (group III, 39 patients),
and severe if indexed EOA<0.65 cm2/m2 (group IV, 36 patients).
Data Collection
Prospective intraoperative and postoperative data were collected from
the registry database. Data related to survival were obtained by telephone
interview with patients, their family, or from the Korean Statistical Infor-
mation Service. The primary end point was all-cause mortality, including
in-hospital mortality. Follow-up information was available on all 351
patients. The closing interval was from March 2011 to April 2011.
Statistical Analysis
In comparing the preoperative characteristics, continuous variables
were expressed as mean  standard deviation, and categorical data wereThe Journal of Thoracic and Cartabulated as frequencies and percentages. For continuous variables, data
were compared using the c2 test or Student t test. All reported probability
values were 2-sided. We analyzed the difference of LVMI according to
postoperative time after AVR using regression analysis, and compared co-
efficient and confidence interval (CI). Overall survival and cardiac-related-
death free survival were calculated using the Kaplan-Meier method and
reported with 95% confidence limits. The effect of PPM on clinical
outcomes after AVR was determined using Cox regression, and results
are expressed as hazard ratio (HR) with 95% CI. Among risk factors, those
with a P value .1 were selected for multivariate analyses. The multivar-
iate model was constructed by the enter method. All data were analyzed
using the SPSS software package for Windows (version 18.0, 2009;
IBM, Armonk, NY).
RESULTS
PPM was nonexistent in 224 patients (group I, 63.8%).
Mild PPM was identified in 52 patients (group II, 14.8%),
moderate PPM was identified in 39 patients (group III,
11.1%), and severe PPM was identified in 36 patients
(group IV, 10.3%). Preoperative and operative patient char-
acteristics are listed in Table 1. Compared with patients
without PPM (group I), those with severe PPM had a higher
prevalence of women (P¼ .05). Most implanted prostheses
were<19 mm in group IV, and mechanical prosthesis was
used more frequently in group I.
In-Hospital Outcomes
In-hospital outcomes are listed in Table 2. Three deaths
occurred in group I (2.3%), 2 in group II (3.8%), 1 in group
III, and none in group IV with no significant differences
among the groups (P ¼ .47). There were also no
differences in the prevalence of postoperative renal failure,
cerebrovascular accident, or bleeding among the groups.
Affect on LVMI
There was significant difference in LVMI regression be-
tween groups (Table 2). The change of LVMI according to
postoperative timewas analyzed. LVMI was decreased after
AVR during follow-up period in all groups irrespective of
presence of PPM (Figure 1). To compare the difference of
LVMI during the follow-up period, we analyzed coefficient
and CI in each group (Figure 2). The bars show the 95% CI,
and the values of group IV showed less negative quantities
than those of others. This shows that LVMI in group IV was
less decreased comparing with group I, II, and III during the
follow-up period after AVR (P<.05).
PPM and Survival
During the follow-up period, the number of deaths was
10 in group I, 5 in group II, 5 in group III, and 8 in group
IV. Overall survival at 4 years was 97.6%  1.6% for
patients in group I, 94.7%  3.7% in group II, 92.2% 
3.7% in group III, and 90.8%  5.1% in group IV. There
were no significant differences in 4-year overall survival
among the groups. However, as time passed overall survival
in group IV decreased gradually, and patients in groups IVdiovascular Surgery c Volume 146, Number 5 1099
TABLE 1. Baseline preoperative and operative data
Group I (n ¼ 224) Group II (n ¼ 52) Group III (n ¼ 39) Group IV (n ¼ 36) P
Age (y) 59.6  11.7 58.9  18.0 59.0  13.0 61.8  14.4 .76
Woman 87 (38.8) 23 (44.2) 13 (33.3) 22 (61.1) .05
NYHA Functional Class>3 14 (6.3) 3 (5.8) 1 (2.6) 2 (5.6) .70
Diabetes mellitus 26 (11.9) 9 (17.6) 9 (25.9) 8 (22.9) .09
Obesity* 76 (33.9) 20 (38.5) 19 (48.7) 15 (41.7) .31
Hypertension 59 (26.3) 11 (21.2) 12 (30.8) 13 (36.1) .43
End-stage renal disease 6 (2.7) 2 (3.9) 0 (0.0) 9 (5.7) .52
Cerebral vascular disease 8 (3.7) 2 (3.9) 2 (5.6) 2 (5.7) .91
Peripheral artery obstructive disease 4 (1.8) 1 (2.0) 0 (0.0) 0 (0.0) .72
Endocarditis 2 (0.9) 2 (3.8) 1 (2.6) 0 (0.0) .32
Ejection fraction<40 (preoperative) 31 (13.8) 10 (19.2) 2 (5.1) 3 (8.3) .19
Ejection fraction (preoperative) 58.5  15.1 58.4  16.8 58.8  13.0 61.4  14.8 .75
LVMI (preoperative g/m2) 175  69.9 190  52.5 175  43.7 171  35.1 .40
Peak pressure gradient (mm Hg) 81.1  18.8 77.8  14.7 78.2  17.4 83.6  20.8 .36
Mean pressure gradient (mm Hg) 50.2  12.2 46.6  11.2 47.6  10.6 51.3  13.9 .18
Mechanical prosthesis 158 (70.5) 31 (59.6) 22 (56.4) 17 (47.2) .01
Prosthesis
21 mm 105 (47) 32 (62) 33 (85) 35 (97) <.05
19 mm 18 (8) 9 (17) 30 (77) 33 (92) <.05
ACC time (min) 103  25.1 91.8  27.9 92.8  25.1 91.3  24.1 .29
CPB time (min) 130  39.7 142  40.1 124  35.6 129  34.6 .73
Values are presented as mean  standard deviation or number (%). NYHA, New York Heart Association; LVMI, left ventricular mass index; ACC, aortic cross clamp; CPB,
cardiopulmonary bypass. *Defined as body mass index>25.
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Overall survival at 12 years was 92.8 2.7% for patients in
in group I, 87.8%  5.6% in group II, 84.7%  6.4% in
group III, and 67.0%  10.1% in group IV (Figure 3). In
patients with preserved left ventricular ejection fraction
(>40%), overall survival at 12 years was 96.0%  1.7%
for patients in group I, and 68.3%  10.5% in group IV
(P ¼ .001).
Multivariate analysis showed that age (HR, 1.24; 95%
CI, 1.10-1.39; P ¼ .01), preoperative left ventricular ejec-
tion fraction (HR, 1.10; 95% CI, 1.02-1.18; P ¼ .01),
New York Heart Association Functional Class IV (HR,
18.7; 95% CI, 1.37-25.5; P ¼ .02), and severe PPM (HR,
6.42; 95% CI, 1.14-35.8; P ¼ .03) were adverse predictors
of overall survival (Table 3).
During the follow-up period, the number of cardiac-
related deaths was 3 in group I, 1 in group II, 1 in group
III, and 4 in group IV. Cardiac-related-death-free survival
at 4 years was 99.6%  0.6% for patients in group I, and
98.1%  1.9%, 96.4%  3.5%, and 97.2%  2.7% inTABLE 2. In-hospital outcomes and left ventricular mass index (LVMI) r
Group I (n ¼ 224) Group II (n ¼
In-hospital mortality 3 (1.3) 2 (3.8)
Renal failure (dialysis) 2 (1.0) 2 (3.8)
Cerebrovascular accident 1 (0.6) 1 (0.8)
Postoperative bleeding 5 (2.0) 1 (0.8)
LVMI regression (g/m2) 57.1  52.0 49.8  37.7
Data are presented as mean  standard error or number (%). LVMI, Left ventricular mass
1100 The Journal of Thoracic and Cardiovascular Surgroups II, III, and IV, respectively, with no statistically sig-
nificant differences between groups. However, cardiac-
related-death-free survival at 12 years was significantly
lower in group IV (81.0%  9.2%) than in groups I, II,
and III (96.3%  2.3%, 98.1%  1.9%, and 96.4% 
3.5%, respectively) (P ¼ .01) (Figure 4).
Multivariate analysis showed that severe PPM was inde-
pendently associated with cardiac-related mortality (HR,
10.4; 95% CI, 1.14-92.1; P ¼ .03), but mild and moderate
PPM were not independent predictors (Table 4).
COMMENT
A small prosthesis may need to be inserted because of
pathologic processes such as annular calcification and fibro-
sis that can reduce the size of the aortic annulus resulting in
a prosthetic EOA less than that of the native valve. The
concept that moderate AS is present in a native valve when
its indexed EOA is< 0.90 cm2/m2 is generally accepted.16
The average mean transvalvular gradient in patients
with PPM, defined as an indexed EOA  0.85 cm2/m2,egression
52) Group III (n ¼ 39) Group IV (n ¼ 36) P
1 (2.8 ) 0 (0.0) .47
1 (3.0) 1 (3.0) .38
0 (0.0) 0 (0.0) .73
0 (0.0) 9 (3.0) .28
44.8  25.1 30.4  22.8 .01
index.
gery c November 2013
FIGURE 1. The change in left ventricular mass index (LVMI) according to postoperative period. A, Group I, patients without prosthesis–patient mismatch
(PPM). Y¼29.377-7.45X, (95% confidence interval [CI],8.507 to6.406; P<.01). B, Group II, patients with mild PPM. Y¼5.877-7.438X, (95% CI,
8.601 to6.274; P<.01). C, Group III, patients with moderate PPM. Y¼21.308-5.807X, (95% CI,7.149 to4.465; P<.01). D, Group IV, patients with
severe PPM. Y ¼15.575-3.286X (95% CI,4.264 to2.308; P<.01).
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patients without PPM and 33 2 mmHg in patients with an
indexed EOA  0.65 cm2/m2.17 Mean gradient increaseFIGURE 2. The difference of change in left ventricular mass index during
the follow-up period.
The Journal of Thoracic and Carduring exercise and average mean gradient in patients
with PPM is close to that of patients with moderate AS.18
This increased transvalvular gradient will result in in-
creased left ventricle work and could decrease the regres-
sion of left ventricular mass.
Could these hemodynamic changes affect patient sur-
vival? There are several reports on the relationship between
PPM and survival. Not only severe PPM but also moderate
PPMmay result in adverse affects on long-term survival af-
ter AVR. Moderate PPM was associated with increased late
mortality in patients with left ventricular dysfunction, and
severe PPM had deleterious influences on both early and
late mortality.19 Considering age, PPM had an adverse in-
fluence on survival for young patients.20 PPM has an influ-
ence on short- and long-termmortality after AVR.20-22 PPM
also has a negative influence on exercise capacity due to
limitation of the increase in cardiac output during
exercise, and has an adverse influence on survival in
young patients.23 However, other studies have reported
that PPM could be common in patients after AVR for aortic
stenosis, but severe mismatch was rare and did not affect
early or late postoperative survival.24 Those studies useddiovascular Surgery c Volume 146, Number 5 1101
TABLE 3. Multivariate analysis of potential independent risk factors
for overall survival after isolated aortic valve replacement in patients
with predominant aortic stenosis during the 12-year follow-up period
Hazard
ratio
95% Confidence
interval P
Woman 0.49 0.19-1.26 .13
Age (y) 1.24 1.10-1.39 .01
Left ventricle ejection
fraction<40%
1.10 1.02-1.18 .01
Left ventricular mass index 1.00 0.99-1.01 .94
Peak pressure gradient 1.02 0.99-1.06 .19
Diabetes mellitus 1.03 0.26-4.02 .96
Obesity* 0.87 0.21-3.54 .85
Hypertension 1.53 0.38-6.08 .53
End-stage renal disease 3.96 0.37-41.7 .17
Cerebrovascular accident 3.39 0.20-53.2 .38
NYHA Functional Class
II 0.17 0.02-1.42 .10
III 0.67 0.09-5.01 .70
IV 18.7 1.37-25.5 .02
Endocarditis 3.87 0.21-70.3 .36
Bioprosthetic valve 0.42 0.13-1.35 .15
In vivo iEOA 0.22 0.01-6.92 .32
PPM
Mild 2.34. 0.57-9.58 .23
Moderate 3.99 0.59-27.0 .15
Severe 6.42 1.14-35.8 .03
NYHA, New York Heart Association; iEOA, in vivo indexed effective orifice area;
PPM, prosthesis-patient mismatch. *Defined as body mass index>25.
FIGURE 3. Overall survival after isolated aortic valve replacement in pa-
tients with predominant aortic stenosis.
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Ddifferent parameters such as time interval, in vitro EOA, or
geometric orifice area, which are heterogeneous character-
istics of patients. These discrepancies show the controversy
surrounding the affect of PPM on survival after AVR. It is
now widely accepted in the American Society of Echocar-
diography/American College of Cardiology/American
Heart Association/European Association of Echocardiogra-
phy guidelines that the in vivo indexed EOA is the only
valid parameter to identify PPM and predict postoperative
gradients and/or adverse clinical outcomes.25 We used the
in vivo indexed EOA, a homogeneous patient group, and
a long-term follow-up period to reduce the bias. Our study
shows that PPM did not affect cardiac-related-death-free
survival at 3 years, but cardiac-related-death-free survival
began to be lower in patients with severe PPM than in those
without PPM or with only moderate PPM after 3 years. This
suggests that PPM did not affect early survival, but did ad-
versely affect long-term survival. Pibarot and colleagues17
reported that cardiac index was similar in patients with
and without PPM up to 3 years after AVR, but decreased
significantly thereafter only in patients with PPM. Consid-
ering this time frame of hemodynamic change, PPM may
affect late survival, but not early survival, in agreement
with our study results.
Patients with left ventricular dysfunction may be espe-
cially vulnerable to the negative effects of PPM. Ruael
and colleagues25 reported that PPM with an indexed EOA1102 The Journal of Thoracic and Cardiovascular Surof 0.85 after AVR primarily affected patients with im-
paired preoperative left ventricle function and resulted in
decreased survival, reduced heart failure-free survival,
and incomplete left ventricular mass regression. In our
study, because 2 or 3 patients showed preoperative left
ventricular dysfunction in Group III or IV, it was difficult
to analyze the relationship. But patients with severe PPM
had a lower overall survival in preserved left ventricle
function, and severe PPM was independent risk factor of
cardiac-related death. Based on this clinical outcome,
more aggressive surgical correction may be needed to
prevent severe PPM when performing AVR.
Thirty-six percent of patients in our study had moderate
or severe PPM, which is not a small percentage of patients.
It has been reported that 20% to 70% of patients undergo-
ing AVR for AS had PPM.15,26 In addition, we used the
in vivo values instead of the in vitro values derived from
premarketing studies, which usually overestimate the
in vivo values by 10% to 15%.26
The proportion of mechanical valve was higher in
patients without PPM than in patients with severe PPM,
and small prostheses<19 mm were implanted predomi-
nantly in patients with severe PPM in our study. It is known
that if compared with stented bioprosthesis, mechanical
valve have a more favorable relationship between its exter-
nal diameter and the EOA.27 Usually, the use of smallgery c November 2013
TABLE 4. Multivariate analysis of potential independent risk factors
for cardiac-related death after isolated aortic valve replacement in
patients with predominant aortic stenosis during the 12-year follow-
up period
Hazard
ratio
95% Confidence
interval P
Woman 2.79 0.22-33.1 .43
Age (y) 1.12 0.96-1.30 .12
Left ventricle ejection
fraction<40%
1.21 1.12-1.34 .04
Left ventricular mass index 1.00 0.98-1.10 .94
Peak pressure gradient 1.02 0.97-1.05 .20
Diabetes mellitus 0.52 0.02-9.33 .65
Obesity* 0.50 0.02-8.64 .63
Hypertension 4.99 0.86-28.9 .07
End-stage renal disease 26.3 0.75-91.7 .07
Cerebrovascular accident 1.30 0.06-24.6 .85
NYHA Functional Class
II 10.6 0.48-235 .13
III 5.97 0.18-196 .31
IV 18.7 2.28-177 .02
Endocarditis 3.87 0.21-70.3 .36
Bioprosthetic valve 0.36 0.03-0.89 .48
In vivo iEOA 0.97 0.03-30.9 .98
PPM
Mild 0.84. 0.02-36.0 .92
Moderate 1.69 0.10-28.5 .71
Severe 10.26 1.14-92.1 .03
NYHA,NewYork Heart Association; iEOA, indexed effective orifice area. PPM, pros-
thesis–patient mismatch. *Defined as body mass index>25.
FIGURE 4. Cardiac-related-death-free survival after isolated aortic valve
replacement in patients with predominant aortic stenosis.
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However, this finding is applicable to Western patients. In
Asian patients who have smaller average body surface areas
than Western patients, the use of prostheses<19 mm would
only be a risk factor for severe PPM.
Considering the change of LVMI with time after AVR,
LVMI was decreased in all patients irrespective of pres-
ence of PPM. But LVMI of patients with severe PPM
was less decreased compared with that of patients without
PPM, or with mild or moderate PPM. Other studies
showed that patients with left ventricular dysfunction and
PPM demonstrated less left ventricular mass regression
compared with patients with left ventricular dysfunction
and without PPM.26 In our study, only patients with severe
PPM demonstrated limited left ventricular mass regression
during a long-term period. In vivo indexed EOAwas not an
independent predictor of cardiac-related or overall mortal-
ity, and patients with mild or moderate PPM had similar
outcomes compared with patients without PPM. Only
patients with severe PPM had significantly worse clinical
outcomes. These findings suggest that relationship be-
tween indexed EOA and risk of mortality may not be linear
and that the influence on clinical outcomes becomes
significant only when the indexed EOA falls into the severe
range.
There are limitations in this study. First, the sample size
was too small to assess the interaction between PPM andThe Journal of Thoracic and Carother factors such as age, body mass index, and left ventric-
ular dysfunction. In particular, the number of patients with
left ventricular dysfunction in Groups III and IV was insuf-
ficient to ensure adequate statistical power for comparing
subgroup analysis. Second, various types of prosthesis
were implanted, so it was difficult to compare according
to type of prosthesis. Third, if the bioprosthesis shows
degenerative change, left ventricular mass regression could
be decreased. Ten or 12 years had passed since some
patients underwent bioprosthesis, and they did not show
degenerative change at the time of our study. There are
many factors that affect survival and may bias outcomes.
Tominimize bias, we included only patients who underwent
first-time isolated AVR for predominant AS and only cases
since 1995 when we began to select various types of pros-
theses. We studied the clinical relationship between PPM
and survival, and further investigation such as pressure
gradient, ejection fraction, and left ventricular mass would
be required to evaluate the influence of PPM on left
ventricle function.
CONCLUSIONS
Patients with severe PPM showed less decrease in LVMI
compared with patients without PPM or with mild or mod-
erate PPM. Severe PPM affected long-term survival but diddiovascular Surgery c Volume 146, Number 5 1103
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Dnot affect early survival. Further, patients with severe PPM
and left ventricle dysfunction could be at increased risk for
cardiac-related death during long-term follow-up period.
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